Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations

Ralph L Sacco, Juhani Sivenius, Hans Christoph Diener

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective: To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups. Design: A post hoc analysis was conducted using data from the European Stroke Prevention Study 2. Rates of annual strokes and vascular events were determined for the aspirin plus extended-release dipyridamole group (n=1650) and the aspirin-only group (n=1649), and were stratified by risk subgroup and univariate risk factors. Stroke models from the Framingham Study and the Stroke Prognostic Instrument II were applied to subjects in the European Stroke Prevention Study 2 to categorize patients into risk groups. Results: Compared with aspirin alone, aspirin plus extended-release dipyridamole demonstrated a more pronounced efficacy in reducing the risk for stroke and vascular events among patients younger than 70 years; those with hypertension, prior stroke, or transient ischemic attack; current smokers; and those with any prior cardiovascular disease. Relative hazard reductions favored the combination of aspirin plus extended-release dipyridamole, and were greatest for the high-risk Framingham Study group and the moderate-risk Stroke Prognostic Instrument II subgroup. Conclusion: Aspirin plus extended-release dipyridamole is more effective than aspirin alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.

Original languageEnglish
Pages (from-to)403-408
Number of pages6
JournalArchives of Neurology
Volume62
Issue number3
DOIs
StatePublished - Mar 1 2005
Externally publishedYes

Fingerprint

Stroke
Population
Aspirin
Blood Vessels
Dipyridamole Drug Combination Aspirin
Efficacy
Transient Ischemic Attack
Cardiovascular Diseases
Hypertension

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. / Sacco, Ralph L; Sivenius, Juhani; Diener, Hans Christoph.

In: Archives of Neurology, Vol. 62, No. 3, 01.03.2005, p. 403-408.

Research output: Contribution to journalArticle

@article{3ec2a00d349e4d338ac52ce8eb193b0a,
title = "Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations",
abstract = "Objective: To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups. Design: A post hoc analysis was conducted using data from the European Stroke Prevention Study 2. Rates of annual strokes and vascular events were determined for the aspirin plus extended-release dipyridamole group (n=1650) and the aspirin-only group (n=1649), and were stratified by risk subgroup and univariate risk factors. Stroke models from the Framingham Study and the Stroke Prognostic Instrument II were applied to subjects in the European Stroke Prevention Study 2 to categorize patients into risk groups. Results: Compared with aspirin alone, aspirin plus extended-release dipyridamole demonstrated a more pronounced efficacy in reducing the risk for stroke and vascular events among patients younger than 70 years; those with hypertension, prior stroke, or transient ischemic attack; current smokers; and those with any prior cardiovascular disease. Relative hazard reductions favored the combination of aspirin plus extended-release dipyridamole, and were greatest for the high-risk Framingham Study group and the moderate-risk Stroke Prognostic Instrument II subgroup. Conclusion: Aspirin plus extended-release dipyridamole is more effective than aspirin alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.",
author = "Sacco, {Ralph L} and Juhani Sivenius and Diener, {Hans Christoph}",
year = "2005",
month = "3",
day = "1",
doi = "10.1001/archneur.62.3.403",
language = "English",
volume = "62",
pages = "403--408",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations

AU - Sacco, Ralph L

AU - Sivenius, Juhani

AU - Diener, Hans Christoph

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Objective: To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups. Design: A post hoc analysis was conducted using data from the European Stroke Prevention Study 2. Rates of annual strokes and vascular events were determined for the aspirin plus extended-release dipyridamole group (n=1650) and the aspirin-only group (n=1649), and were stratified by risk subgroup and univariate risk factors. Stroke models from the Framingham Study and the Stroke Prognostic Instrument II were applied to subjects in the European Stroke Prevention Study 2 to categorize patients into risk groups. Results: Compared with aspirin alone, aspirin plus extended-release dipyridamole demonstrated a more pronounced efficacy in reducing the risk for stroke and vascular events among patients younger than 70 years; those with hypertension, prior stroke, or transient ischemic attack; current smokers; and those with any prior cardiovascular disease. Relative hazard reductions favored the combination of aspirin plus extended-release dipyridamole, and were greatest for the high-risk Framingham Study group and the moderate-risk Stroke Prognostic Instrument II subgroup. Conclusion: Aspirin plus extended-release dipyridamole is more effective than aspirin alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.

AB - Objective: To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups. Design: A post hoc analysis was conducted using data from the European Stroke Prevention Study 2. Rates of annual strokes and vascular events were determined for the aspirin plus extended-release dipyridamole group (n=1650) and the aspirin-only group (n=1649), and were stratified by risk subgroup and univariate risk factors. Stroke models from the Framingham Study and the Stroke Prognostic Instrument II were applied to subjects in the European Stroke Prevention Study 2 to categorize patients into risk groups. Results: Compared with aspirin alone, aspirin plus extended-release dipyridamole demonstrated a more pronounced efficacy in reducing the risk for stroke and vascular events among patients younger than 70 years; those with hypertension, prior stroke, or transient ischemic attack; current smokers; and those with any prior cardiovascular disease. Relative hazard reductions favored the combination of aspirin plus extended-release dipyridamole, and were greatest for the high-risk Framingham Study group and the moderate-risk Stroke Prognostic Instrument II subgroup. Conclusion: Aspirin plus extended-release dipyridamole is more effective than aspirin alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=14844301718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844301718&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.3.403

DO - 10.1001/archneur.62.3.403

M3 - Article

C2 - 15767505

AN - SCOPUS:14844301718

VL - 62

SP - 403

EP - 408

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 3

ER -